Bavarian Nordic completes delivery of smallpox vaccine to U.S. stockpile

Bavarian Nordic A/S, an international biotechnology company, announced on Friday it completed the delivery of 20 million doses of IMVAMUNE smallpox vaccine to the U.S. Strategic National Stockpile.

The completion of the order resulted from a decade-long research and development partnership between the U.S. government and Bavarian Nordic. The order fulfills an original contract awarded in 2007 that was valued at $549 million.

Since 2010, Bavarian Nordic supplied the vaccine to the SNS to use in the event of a smallpox emergency in the U.S.

"Bavarian Nordic is proud to be a part of fulfilling a U.S. government requirement for bioterrorism preparedness by delivering 20 million doses of IMVAMUNE," Anders Hedegaard, the president and CEO of Bavarian Nordic, said. "This accomplishment shows that when resources and commitment are applied, industry and government can successfully work together to achieve great things."

The vaccine is being stockpiled by the U.S. for emergency use in individuals with compromised immune systems, including children and pregnant and nursing women, who were not recommended to take the previous generation vaccine.

In April, the U.S. signed a new contract with Bavarian Nordic valued at up to $228 million to supply eight million added doses of IMVAMUNE required to maintain the 20 million-dose stockpile over time.